Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Buy
59
CLLS Quote, Financials, Valuation and Earnings
Last price:
$1.89
Seasonality move
:
-14.33%
Day range:
$1.89 - $2.06
52-week range:
$1.10 - $2.43
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.08x
P/B ratio:
1.72x
Volume:
131.5K
Avg. volume:
104.1K
1-year change:
-8.29%
Market cap:
$199.6M
Revenue:
$41.5M
EPS (TTM):
-$0.61
Analysts' Opinion
-
Consensus RatingCellectis SA has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.75, Cellectis SA has an estimated upside of 188.95% from its current price of $1.99.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $1.99.
Fair Value
-
According to the consensus of 3 analysts, Cellectis SA has 188.95% upside to fair value with a price target of $5.75 per share.
CLLS vs. S&P 500
-
Over the past 5 trading days, Cellectis SA has overperformed the S&P 500 by 22.38% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Cellectis SA does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cellectis SA has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Cellectis SA reported revenues of $10.7M.
Earnings Growth
-
Cellectis SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Cellectis SA reported earnings per share of -$0.18.
Enterprise value:
8.7M
EV / Invested capital:
--
Price / LTM sales:
4.08x
EV / EBIT:
--
EV / Revenue:
0.18x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.35x
Price / Operating cash flow:
7.72x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$38.8M
Return On Assets:
-15.89%
Net Income Margin (TTM):
-127.08%
Return On Equity:
-49.15%
Return On Invested Capital:
-35.55%
Operating Margin:
-133.07%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $17.6M | $5.1M | $47.6M | $4.5M | $10.7M | |
| Gross Profit | $10.4M | -$2.5M | $38.8M | $2.2M | $8.6M | |
| Operating Income | -$83.9M | -$94.8M | -$52.8M | -$20.9M | -$14.2M | |
| EBITDA | -$76.4M | -$58.2M | -$32.5M | $11.7M | -$11.3M | |
| Diluted EPS | -$2.22 | -$1.34 | -$0.61 | -$0.15 | -$0.18 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $272.4M | $195.2M | $137.4M | $258.1M | $271.8M | |
| Total Assets | $442.7M | $347.2M | $251.4M | $354.5M | $364.1M | |
| Current Liabilities | $46.9M | $52.3M | $60.5M | $158.4M | $162.6M | |
| Total Liabilities | $153M | $144.1M | $130.9M | $263.9M | $247.9M | |
| Total Equity | $289.7M | $203.1M | $120.5M | $90.6M | $116.2M | |
| Total Debt | $23.3M | $20.6M | $17.6M | $45.2M | $50.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$79.2M | -$19.7M | $29.1M | -$23.3M | -$17.2M | |
| Cash From Investing | -$1.5M | -$17.8M | -$96.5M | -$2.1M | $4.2M | |
| Cash From Financing | $13.2M | $75M | $73.1M | $11.9M | -$4.1M | |
| Free Cash Flow | -$81.2M | -$20.9M | $25.2M | -$23.6M | -$17.6M | |
CLLS
Sector
Market Cap
$199.6M
$34.4M
Price % of 52-Week High
81.89%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
-66.43%
-1.01%
1-Year Price Total Return
-8.3%
-37.36%
Beta (5-Year)
2.910
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.79
200-day SMA
Buy
Level
$1.63
Bollinger Bands (100)
Buy
Level
1.27 - 1.61
Chaikin Money Flow
Buy
Level
789.7K
20-day SMA
Buy
Level
$1.61
Relative Strength Index (RSI14)
Buy
Level
68.10
ADX Line
Buy
Level
34.47
Williams %R
Neutral
Level
-38.9088
50-day SMA
Buy
Level
$1.53
MACD (12, 26)
Buy
Level
0.53
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
952.1K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.6608)
Sell
CA Score
(Annual)
Level (-1.7044)
Sell
Beneish M-Score
(Annual)
Level (50.3205)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (2.8783)
Buy
Piotroski F Score
(Annual)
Level (7)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Stock Forecast FAQ
In the current month, CLLS has received 1 Buy ratings 2 Hold ratings, and 0 Sell ratings. The CLLS average analyst price target in the past 3 months is $5.75.
-
Where Will Cellectis SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cellectis SA share price will rise to $5.75 per share over the next 12 months.
-
What Do Analysts Say About Cellectis SA?
Analysts are divided on their view about Cellectis SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cellectis SA is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is Cellectis SA's Price Target?
The price target for Cellectis SA over the next 1-year time period is forecast to be $5.75 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is CLLS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cellectis SA is a Hold. 2 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of CLLS?
You can purchase shares of Cellectis SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cellectis SA shares.
-
What Is The Cellectis SA Share Price Today?
Cellectis SA was last trading at $1.89 per share. This represents the most recent stock quote for Cellectis SA. Yesterday, Cellectis SA closed at $1.99 per share.
-
How To Buy Cellectis SA Stock Online?
In order to purchase Cellectis SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
How High Can SharkNinja Stock Go?
If you know popular consumer appliance brands Shark and Ninja,…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 8.72% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 0.47% over the past day.
Sell
42
VLCN alert for Jul 17
Volcon [VLCN] is up 203% over the past day.
